High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial.

While the difference failed to reach statistical significance, the 71% relative risk reduction in the primary outcome and significant differences in exploratory outcomes like EtO 2 , suggest a potential benefit from HFNC that should be evaluated in future research.

also in 6,035 other papers